- Home
- / Deciphera Pharmaceuticals
Deciphera Pharmaceuticals
Stock Price
$14.5
2023-09-01
Market Capitalization
$1.1 B
2023-09-01
Deciphera Pharmaceuticals Summary
Company Summary
- Overview
- Deciphera Pharmaceuticals is a clinical-stage biopharmaceutical company that develops medicines for patients with cancer. It utilizes its drug discovery platform and designs kinase inhibitors. The pipeline includes ripretinib, vimseltinib, rebastinib, and DCC-3116.
- Type
- Public
- Status
- Active
- Founded
- 2003
- HQ
- Waltham, MA, US | view all locations
- Website
- https://www.deciphera.com/
- Cybersecurity rating
- ESG rating
Table of Contents
Key People
Daniel L. Flynn, Executive Vice President, Chief Scientific Officer and Founder
Jeff Held, Senior Vice President, General Counsel
Caroline Chevalier, Vice President, Human Resources
Operating MetricsView all
Patents (US)
11
Aug, 2017
Patents (Foreign)
47
Aug, 2017
Patent Applications
49
Aug, 2017
LocationsView all
2 locations detected
Waltham, MA HQ
United States
200 Smith St
Lawrence, KS
United States
643 Massachusetts St, Suite 200
Deciphera Pharmaceuticals Financials
Summary Financials
- Net income (Q3, 2017)
- ($12.0M)
- Cash (Q3, 2017)
- $82.1M
- EBIT (Q3, 2017)
- ($12.2M)